Entrada Therapeutics Inc. (TRDA)
Entrada Therapeutics to Present at Upcoming Investor Conferences
Ocular Therapeutix Inc (OCUL)
Ocular Therapeutix™ to Report Third Quarter 2025 Financial Results on November 4, 2025
Kymera Therapeutics Inc (KYMR)
Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025
Alkermes plc (ALKS)
Alkermes plc Reports Third Quarter 2025 Financial Results
Natera Inc (NTRA)
Natera Reports Strong Advanced Adenoma Data from Prospective PROCEED-CRC Trial, Demonstrating 22.5% Sensitivity and 91.5% Specificity
IQVIA Holdings Inc. (IQV)
IQVIA Reports Third-Quarter 2025 Results
Nutriband Inc. (NTRB)
Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch
Tenet Healthcare Corporation (THC)
Tenet Reports Strong Third Quarter 2025 Results; Raises 2025 Financial Outlook
Merck & Company Inc (MRK)
Merck Announces KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Clear Cell Renal Cell Carcinoma (RCC) Following Nephrectomy
Avidity Biosciences Inc (RNA)
RNA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Avidity Biosciences, Inc. Is Fair to Shareholders